Data Readout

PALIZADE Data Already Show 42% CRR Rate Before Kezar's Terminated Trial Closes Out

Kezar's Phase 2b lupus nephritis trial was terminated in November 2024, but ClinicalTrials.gov results already show a Week 25 renal response signal; the AppliedXL model puts endpoint-met probability at 4.1%.

By AppliedXLJuly 13, 2026Trial NCT05781750

Executive Summary

Kezar Life Sciences terminated the Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis in November 2024, yet ClinicalTrials.gov already carries posted outcome tables, including a Week 25 secondary finding that 42% of patients on the 60 mg dose reached UPCR ≤0.5 versus 21% on placebo Press Release.
The registered primary endpoint, complete renal response at Week 37, has posted outcome tables but the resolved participant counts and statistical comparison are not disclosed in the dossier, leaving the headline efficacy question unanswered.
AppliedXL's endpoint-met probability sits at 4.1% with LOW confidence and a wide uncertainty band, a read the model itself flags as resting on operational and target-biology features rather than mechanism-fit evidence, which points the other way [AXL-MODEL].
No other sponsor is currently running an active PSMB8-targeted trial in lupus nephritis, and the broader target-indication intersection shows a 50% historical termination rate across just two trials, meaning this result carries limited head-to-head competitive weight.
The catalyst turns less on a blind topline surprise and more on how Kezar interprets an already-partially-disclosed, immature dataset from a trial it stopped early.

The disclosed signal

Kezar Life Sciences expects to report topline data from PALIZADE, its Phase 2b placebo-controlled trial of zetomipzomib in active lupus nephritis, sometime in the second half of 2026 NCT05781750. But ClinicalTrials.gov already carries posted outcome tables from the trial, which Kezar terminated on November 19, 2024, after suspending it on October 4, 2024. At Week 25, a secondary timepoint, 42% of patients on the 60 mg dose achieved a urine protein-to-creatinine ratio (UPCR) of 0.5 or below, a marker of kidney inflammation, compared with 21% on placebo; the 60 mg arm also showed a 64% reduction in SLEDAI-2K, a composite lupus disease-activity score, at the same timepoint Press Release. The registered primary endpoint, complete renal response at Week 37, has posted outcome tables but the dossier does not disclose the resolved result for that measure.

Probability of Success

Endpoint Met4%

Completes48%

Clinical Significance9%

Regulatory50%

Why the trial stopped

PALIZADE enrolled 84 patients across 12 countries starting in November 2023, with a primary completion date of November 8, 2024 NCT05781750. The trial was suspended, then terminated, within six weeks of that primary completion date, and the dossier does not disclose why. AppliedXL's own risk assessment flags the trial with a Critical risk score of 100, citing enrollment underperformance and status problems as high-severity signals. Protocol-stability tracking shows zero substantive amendments beyond status changes, a 'Stable' proxy label that reflects registry field activity rather than the underlying reason for the early stop.

What the model rests on

AppliedXL's endpoint-met probability for the primary complete-renal-response endpoint stands at 4.1%, carrying a LOW confidence label and a wide uncertainty band [AXL-MODEL]. The model's read leans on operational design features, enrollment per arm, country count, and regulatory jurisdiction count, alongside target-biology signals like off-target tissue expression, rather than on mechanism-indication fit, which itself scores low at 0.24 [AXL-MODEL]. That mix means the 4.1% figure is a statistically derived estimate calibrated mostly to trial structure and historical phase base rates, not a mechanism-grounded clinical judgment, and it should be read with that caveat.

Competitive and target context

No direct same-target, same-indication comparator exists for zetomipzomib in lupus nephritis; the closest same-drug precedent is Kezar's own Phase 2 autoimmune hepatitis program, which shares the PSMB8 target but a different disease. The broader PSMB8-in-lupus-nephritis intersection includes just two trials from a single sponsor, with a 50% historical termination rate, and the target's field activity has declined to zero recent trials versus 36 older ones. Modality-precedent competitors in lupus nephritis, including Aurinia's voclosporin and Viatris's cenerimod, target different mechanisms (cyclophilin and S1P1, respectively) and are not direct comparators to an immunoproteasome inhibitor.

Safety in context

Adverse-event tables from the terminated trial show deaths in all three arms: 2 of 27 patients on 30 mg, 1 of 29 on 60 mg, and 1 of 28 on placebo, with serious adverse events in 5, 8, and 3 patients respectively. AppliedXL characterizes the overall safety profile as consistent with prior known events for the drug Press Release. Combined with the model's explicit immature_data and post_hoc_emphasis flags on the efficacy result, the safety and efficacy signals together support further study rather than a decision-grade conclusion Press Release.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.